Beyond Statins: The Molecular Evolution of Lipid-Lowering Therapies

Since their introduction in the late 1980s, statins have been the foundation of lipid - lowering therapy, reducing cardiovascular morbidity and mortality by inhibiting HMG-CoA reductase, which is a rate limiting enzyme in cholesterol biosynthesis. However, a large proportion of patients either fail to achieve target low density lipoprotein cholesterol (LDL-C) levels on statins alone, or experience adverse side effects that limit their use. This gap has increased the development of novel agents that work through distinct molecular mechanisms.

One of the advances is the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. PCSK9 is a hepatic protein that binds LDL receptors and targets them for lysosomal degradation by diminishing the liver's capacity to digest LDL-C. PCSK9 is synthesized as a zymogen in hepatocytes and undergoes autocatalytic cleavage in the endoplasmic reticulum before secretion. Once in the blood, it binds to the epidermal domain of the LDL receptor. This alters receptor conformation so that instead of recycling back to the hepatocyte surface, the receptor moves towards lysosomal degradation. Monoclonal antibodies such as alirocumab neutralize circulating PCSK9, preventing this degradation and increasing receptor recycling. Clinical trials have consistently shown LDL-C reductions of 50%-60% beyond statin therapy, with parallel decreases in cardiovascular events. These results established this inhibitor as the first transformative advance in lipid lowering therapy since statins.

Adding to this, RNA based therapeutics offer another alternative. Inclisiran, a small interfering RNA, is designed to destroy PCSK9 mRNA in hepatocytes. Rather than neutralizing the protein in circulation, it stops its production at the translational level. Inclisiran enters hepatocytes via conjugation to N-acetylgalactosamine, which binds the asialoglycoprotein receptor and allows selective liver uptake. Once inside the cell, the antisense strand is incorporated into the RNA-induced silencing complex, which prevents their conversion into proteins. This yield sustained LDL-C reductions with only twice a year dosing which is an advantage for patients. Similarly, antisense oligonucleotides (AOSs) expand the therapy. For example, Volanesorsen reduces the expression of apolipoprotein C-III, an inhibitor of lipase, leading to reductions in triglycerides among patients with severe hypertriglyceridemia. Such therapies show the capacity of RNA based drugs to target molecules beyond LDL-C regulation. This widens the scope of dyslipidemia management.

These innovations show a trajectory in lipid pharmacology, moving from broad enzyme inhibition towards therapies that modulate protein function and gene expression. The diversity of mechanisms allows clinicians to tailor treatment better to specific patients either with statin intolerance or genetic dyslipidemias. Therapies are evolving into precision based models that can be better suited for patient care. This shift broadens the scope of lipid management and helps scientists' understanding of cholesterol and triglyceride regulation at the cellular level.



TARINI KILACHAND



CITATIONS

1. Blom, Dirk, et al. “RNA-Based Therapy in the Management of Lipid Disorders: A Review.” Lipids in Health and Disease, vol. 21, no. 1, 23 Apr. 2022, https://doi.org/10.1186/s12944-022-01649-3.
2. Cleveland Clinic. “PCSK9 Inhibitors: How They Manage Cholesterol and Side Effects.” Cleveland Clinic, 17 Feb. 2022, my.clevelandclinic.org/health/drugs/22550-pcsk9-inhibitors.
3. ---. “Statins: Types, Uses and Side Effects.” Cleveland Clinic, 12 Mar. 2024, my.clevelandclinic.org/health/treatments/22282-statins.
4. Hajar, Rachel. “PCSK 9 Inhibitors: A Short History and a New Era of Lipid-Lowering Therapy.” Heart Views, vol. 20, no. 2, 2019, p. 74, https://doi.org/10.4103/heartviews.heartviews_59_19.
5. “PCSK9 Inhibition: A Game Changer in Cholesterol Management - Mayo Clinic.” Mayoclinic.org, 2018, www.mayoclinic.org/medical-professionals/cardiovascular-diseases/news/pcsk9-inhibition-a-game-changer-in-cholesterol-management/mac-20430713.
6. Zhu, Yiran, et al. “RNA-Based Therapeutics: An Overview and Prospectus.” Cell Death & Disease, vol. 13, no. 7, 23 July 2022, pp. 1–15, www.nature.com/articles/s41419-022-05075-2, https://doi.org/10.1038/s41419-022-05075-2.